is the Aftercare Research Program?
The Aftercare Research Program at the the Jane and Terry Semel
Institute for Neuroscience and Human Behavior at UCLA is an outpatient
research clinic that provides free treatment and assessments for
patients who are participating in clinical research designed to
improve our understanding of psychotic disorders and to develop
more effective treatments.
Participants in the study receive an initial diagnostic interview
to determine eligibility and receive treatment at the UCLA NPI&H
Aftercare Research Program, which includes individual case management,
group therapy, and the antipsychotic
medication risperidone, free of charge for about one year. Patients' family
members will be invited to join family psychoeducational meetings. An initial
period on risperidone is a requirement of this study, so a change of medication
may be needed.
directs the study?
Keith H. Nuechterlein, Ph.D., Professor, UCLA Department of Psychiatry,
is the Director of the UCLA Aftercare Research Program.
If you are interested in obtaining more information and/or
in referring someone for possible participation, contact
Nicole DeTore, M.S., e-mail: firstname.lastname@example.org or
Luana Turner, Psy.D., e-mail: email@example.com.
You can also call us at (310) 206-3142, or email us at Aftercare@mednet.ucla.edu
Cognition and Work Outcome Study
Patients in the Aftercare Research Program will also participate in a study
that will examine whether we can improve our treatments that aim to get young
patients who have recently developed a psychotic disorder back to work or school
in order to prevent the onset of chronic disability. After stabilization on oral
risperidone, the patients will be randomized to treatment with either oral risperidone
or injectable risperidone (Risperdal Consta). In addition, all patients will
be randomized to either cognitive enhancement treatment using specialized computer
software programs, or to a treatment intended to enhance quality of life through
healthy lifestyle changes (improved nutrition, exercise, and stress management).
All patients will receive case management and individualized placement and support
services to help them return to work (or school). We are currently enrolling
participants. Each patient will be followed for approximately 1½ years.
Keith Nuechterlein, Ph.D., the Director of the Aftercare Research Program is
the Principal Investigator for this study.
Dr. Nuechterlein presented an overview of the last 20 years of research
conducted at the UCLA Aftercare Research Program at the Semel Institute
Grand Rounds on November 1, 2005.